Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China's CANbridge Partners with Amoy on Diagnostic For Brain Cancer Drug

publication date: May 16, 2017
Beijing's CANbridge Life Sciences partnered with Amoy Diagnostics of Xiamen, China to develop a companion diagnostic assay for CANbridge’s lead candidate, a treatment for glioblastoma multiforme. In European trials, CAN008 provided a significant overall survival benefit for recurrent GBM patients with high expression of the CD95 ligand, or low methylation of a CD95L promotor, CpG2. CAN008  is currently being tested in Phase I/II clinical study among GBM patients in Taiwan. CANbridge plans to start a China Phase II trial of CAN008 next year. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital